PDF(Pubmed)
Abstract：
BACKGROUND: Neoadjuvant immunochemotherapy can effectively downstage tumors and reduce the risk of postoperative recurrence and distant metastasis in patients with non-small cell lung cancer (NSCLC). In this study, we investigated the correlation between inflammatory biomarkers and tertiary lymphoid structure (TLS) expression. We also compared the predictive values of these inflammatory parameters, TLSs, and a combination of inflammatory parameters and TLSs for neoadjuvant efficacy in patients with NSCLC.
METHODS: We retrospectively analyzed the clinical information of 106 patients with NSCLC who underwent neoadjuvant immunochemotherapy and radical surgery at Shandong Cancer Hospital between June 2020 and June 2022.
RESULTS: TLS was evaluated using hematoxylin-eosin staining and immunohistochemically-stained tissue sections. Logistic analysis was performed to determine the correlation between inflammatory parameters, TLSs, and the factors affecting major pathological response (MPR). Receiver operating characteristic curves and the C-index were used to evaluate the predictive value of the nomogram models for MPR. The systemic immune-inflammatory index (SII) was an independent predictor of high TLS abundance and maturity. Platelet-to-lymphocyte ratio (PLR) ≤201.8, TLS abundance, and TLS maturity were independent predictors of MPR. The PLR-TLS combined model performed better in assessing the MPR in patients with NSCLC than models using single indicators.
CONCLUSIONS: Our study demonstrated that the SII is an independent predictor of both TLS abundance and maturity. Both TLSs and PLR can predict MPR rates in patients with NSCLC receiving neoadjuvant immunochemotherapy. However, assessing the MPR in patients with NSCLC using a combination of PLR and TLSs is more accurate than using either indicator alone.
METHODS: We retrospectively analyzed the clinical information of 106 patients with NSCLC who underwent neoadjuvant immunochemotherapy and radical surgery at Shandong Cancer Hospital between June 2020 and June 2022.
RESULTS: TLS was evaluated using hematoxylin-eosin staining and immunohistochemically-stained tissue sections. Logistic analysis was performed to determine the correlation between inflammatory parameters, TLSs, and the factors affecting major pathological response (MPR). Receiver operating characteristic curves and the C-index were used to evaluate the predictive value of the nomogram models for MPR. The systemic immune-inflammatory index (SII) was an independent predictor of high TLS abundance and maturity. Platelet-to-lymphocyte ratio (PLR) ≤201.8, TLS abundance, and TLS maturity were independent predictors of MPR. The PLR-TLS combined model performed better in assessing the MPR in patients with NSCLC than models using single indicators.
CONCLUSIONS: Our study demonstrated that the SII is an independent predictor of both TLS abundance and maturity. Both TLSs and PLR can predict MPR rates in patients with NSCLC receiving neoadjuvant immunochemotherapy. However, assessing the MPR in patients with NSCLC using a combination of PLR and TLSs is more accurate than using either indicator alone.
摘要：
背景：新辅助免疫化疗可以有效降低非小细胞肺癌（NSCLC）患者的肿瘤分期，降低术后复发和远处转移的风险。在这项研究中,我们研究了炎症生物标志物与三级淋巴结构(TLS)表达之间的相关性.我们还比较了这些炎症参数的预测值，TLSs,以及炎性参数和TLSs的组合对NSCLC患者的新辅助疗效。
方法：回顾性分析2020年6月至2022年6月山东省肿瘤医院106例接受新辅助免疫化疗和根治术的非小细胞肺癌患者的临床资料。
结果：使用苏木精-伊红染色和免疫组织化学染色的组织切片评估TLS。进行Logistic分析以确定炎症参数之间的相关性。TLSs,以及影响主要病理反应（MPR）的因素。使用受试者工作特征曲线和C指数来评估列线图模型对MPR的预测值。全身免疫炎症指数（SII）是高TLS丰度和成熟度的独立预测因子。血小板与淋巴细胞比率（PLR）≤201.8，TLS丰度，TLS成熟度是MPR的独立预测因子。与使用单一指标的模型相比，PLR-TLS组合模型在评估NSCLC患者的MPR方面表现更好。
结论：我们的研究表明，SII是TLS丰度和成熟度的独立预测因子。TLS和PLR都可以预测接受新辅助免疫化疗的NSCLC患者的MPR率。然而,联合使用PLR和TLSs评估NSCLC患者的MPR比单独使用任一指标更准确.
方法：回顾性分析2020年6月至2022年6月山东省肿瘤医院106例接受新辅助免疫化疗和根治术的非小细胞肺癌患者的临床资料。
结果：使用苏木精-伊红染色和免疫组织化学染色的组织切片评估TLS。进行Logistic分析以确定炎症参数之间的相关性。TLSs,以及影响主要病理反应（MPR）的因素。使用受试者工作特征曲线和C指数来评估列线图模型对MPR的预测值。全身免疫炎症指数（SII）是高TLS丰度和成熟度的独立预测因子。血小板与淋巴细胞比率（PLR）≤201.8，TLS丰度，TLS成熟度是MPR的独立预测因子。与使用单一指标的模型相比，PLR-TLS组合模型在评估NSCLC患者的MPR方面表现更好。
结论：我们的研究表明，SII是TLS丰度和成熟度的独立预测因子。TLS和PLR都可以预测接受新辅助免疫化疗的NSCLC患者的MPR率。然而,联合使用PLR和TLSs评估NSCLC患者的MPR比单独使用任一指标更准确.
